ClinicalTrials.gg
CompletedNCT03988504Updated Jun 17, 2019

Impact of Predictive Genetic Testing

An observational study in Genetic Testing, Quality of Life and Physical Activity, sponsored by Robert Bosch Medical Center. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-17.

Sponsored by Robert Bosch Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
241
Ages
18 Years and older
Sex
All
01

Study summary

Analysing Impact of preemptive genetic testing on quality of life, physical activity and eating behavior at baseline and 3 months after testing.

02

Conditions studied

  • Genetic Testing
  • Quality of Life
  • Physical Activity

Browse trials for

03

In context

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

This study's enrollment of 241 is above the median of 98 across 1,240 observational studies indexed under Motor Activity.

Browse Motor Activity studies →

Lead sponsor

Robert Bosch Medical Center is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Healthy subjects with request for health check up at Robert-Bosch-Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • for genetic testing
  • informed consent for study participation

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • renal replacement dependency
  • pregnancy
  • active cancer disease
  • no for genetic testing or study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
241 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testRoutine check up including genetic testing

    Intervention is a routine check up including preemptive genetic testing

06

What researchers measure

Primary outcomes

  1. Quality of Life assessed by the SF-36 questionnaire [followed by its scale information in the Description]

    Short form (36) (SF-36) questionnaire evaluates health related quality of life (Scale 0-100)

    Time frame: 3 months

  2. Physical activity assessed by the IPAQ questionnaire [followed by its scale information in the Description]

    International Physical Activity Questionnaire (IPAQ) evaluates physical activity in MET(metabolic equivalent)/min/week

    Time frame: 3 months

  3. Eating behavior assessed by the modified LEI questionnaire [followed by its scale information in the Description]

    The modified Luzerner Ernaehrungs Index (LEI) questionnaire evaluates eating behavior at lunch (Scale 1-4 per item; 1=never; 4=daily)

    Time frame: 3 months

Secondary outcomes

  1. Satisfaction with check up and genetic testing: Likert scale (1-10)

    Likert scale (1-10)

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — On request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jan 2018, 16 months.

Of 492 non-industry observational studies under Motor Activity, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's 16 months is below that.

Counting every sponsor, half of 502 studies reached it within 22 months; a quarter within 8 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2019
First posted
Jun 17, 2019
StartActual
Sep 1, 2016
Primary completionActual
Jan 31, 2018
CompletionActual
Jan 31, 2018
Last update
Jun 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03988504
Lead sponsor
Robert Bosch Medical Center
Responsible party
Prof. Dr. med. Mark Dominik Alscher (Medical Director, Managing Director, Robert Bosch Medical Center) — Principal investigator
First posted
Jun 17, 2019
Start date
Sep 1, 2016
Primary completion
Jan 31, 2018
Completion
Jan 31, 2018
Last update
Jun 17, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion